Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 17/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4163140 | 0.99 | PTGER1 (0.72) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 | |
| SCHEMBL13902737 | 0.87 | PTGER1 (0.80) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 | |
| SCHEMBL4152215 | 0.84 | PTGER1 (1.00) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 | |
| SCHEMBL13874441 | 0.84 | PTGER1 (0.73) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 | |
| SCHEMBL4067224 | 0.83 | PTGER1 (0.82) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 | |
| SCHEMBL2953318 | 0.83 | PTGER1 (1.00) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 | |
| Hydrochloric Acid SCHEMBL4074271 | 0.83 | PTGER1 (0.72) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL4076147 | 0.82 | PTGER1 (0.74) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 | |
| SCHEMBL14098775 | 0.82 | PTGER1 (0.52) | PTGER1TBXA2RPTGER3PPARG | |
| Hydrochloric Acid SCHEMBL4164327 | 0.81 | PTGER1 (0.73) | PTGER1CYP1A2CYP2C9TBXA2RPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099177-A1 | PYRIDYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099177-A1 | PYRIDYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2013181-A1 | PYRIDYL COMPOUNDS | Glaxo Group Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007128752-A1 | PYRIDYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099177-A1 | PYRIDYL COMPOUNDS | CYP2C19, CYP4F3, C5 | PTGER1 180/4885CYP1A2 24/4885CYP2C9 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.